CA125 is a high molecular weight mucin-type glycoprotein, originally defined by the Oc125 monoclonal antibody (MAb) established by Bast et al.1. Different epitopes, co-expressed with the Oc125 epitope on the CA125 antigen, have been used for the development of heterologous assays for determination of the CA125 antigen2. The CA125 EIA is based on two mouse monoclonal antibodies, Ov197 and Ov185, directed against two independent epitopes of the protein core of the CA125 antigen3, 4. Assays for CA125 are frequently used to monitor patients with gynecological malignancies such as epithelial ovarian cancer5.
Bast R., Feeney M., Lazarus H., Nadler L., Colvin R., Knapp R., (1981). Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68: 1331 - 1337.
O'Brien T, Raymond L, Bannon G, Ford D, Hardardottir H, Miller F, Quirk J (1991). New monoclonal antibodies identify the glycoprotein carrying the CA125 epitope. Am J Obstet Gynecol 165: 1857 - 1864.
Nilsson O, Jansson E-L, Dahlen U, Nilsson K, Nustad K, Högberg T, Lindholm L (1994). In: Current Tumor Diagnosis: Applications, Clinical Relevance, Research, Trends. Ed R. Klapdor. Zuckswerdt Verlag München, pp 401-405.
Nustad K. et al., (1996) Specificity and affinity of 26 monoclonal antibodies against the CA125 antigen: First report from the ISOBM TD-1 Workshop. Tumor Biol 17:196-219.
Bonfrer J., Duffy M., Radtke, M., Segurado O., Torre G., van Dalen A., Zwirner M. (1999) Tumor markers in gynecological cancers-EGTM recommendations. Anticancer Research 19:2785-2820.
CanAg CA125 EIA
For 96 determinations
Please contact your local Fujirebio representative for the availability of this product in your country.
Browse regulatory documents for this product
Create a (free!) eServices account and start browsing all regulatory documentation right away.